Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-1189 in HIV-associated cognitive and motor impairment
NCT00002414Phase 2Unknown
- Sponsor
- Centaur Pharmaceuticals
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of REN-1654 in AIDS Dementia Complex (HAD) (3 arms), sponsored by Centaur Pharmaceuticals. Primary endpoint: Safety and Tolerability Assessment at Week 22. Status: unknown.
02
Drugs
REN-1654
03
Conditions
AIDS Dementia Complex (HAD)
Beyond the preview
Go deeper on NCT00002414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002414.